Ivermectin Treatment in Patients With Onchocerciasis-Associated Epilepsy: Protocol of a Randomized Clinical Trial

Robert Colebunders, Michel Mandro, Deby Mukendi, Housseini Dolo, Patrick Suykerbuyk, Marieke Van Oijen, Robert Colebunders, Michel Mandro, Deby Mukendi, Housseini Dolo, Patrick Suykerbuyk, Marieke Van Oijen

Abstract

Background: Many studies have reported an association between epilepsy, nodding syndrome (NS), and onchocerciasis (river blindness). A high prevalence of epilepsy has been noted particularly in onchocerciasis hyperendemic areas where onchocerciasis is not or insufficiently controlled with mass ivermectin distribution. There is evidence that increasing the coverage of ivermectin reduces the incidence of epilepsy, and anecdotal evidence suggests a reduction in seizure frequency in onchocerciasis-associated epilepsy (OAE) patients who receive ivermectin. Finding an alternative treatment for epilepsy in these patients will have major consequences.

Objective: The goal of the study is to assess whether ivermectin treatment decreases the frequency of seizures and leads to seizure freedom in OAE patients, including patients with NS. If we are able to demonstrate such an effect, this would strengthen the argument that onchocerciasis is causing epilepsy and therefore we should increase our efforts to eliminate onchocerciasis.

Methods: We will conduct a randomized clinical trial in the Democratic Republic of Congo to compare seizure freedom in onchocerciasis-infested epilepsy patients who receive immediate ivermectin treatment with delayed (after 4 months) ivermectin treatment. All participants will simultaneously receive antiepilepsy drugs (AEDs) according to local guidelines for epilepsy treatment. The primary endpoint is seizure freedom defined as no seizures during the 4 month of follow-up. Secondary endpoint is significant (>50%) seizure reduction compared to baseline seizure frequency. Reduction of seizures will be compared between ivermectin and nonivermectin arms.

Results: Start of enrollment is planned for August 2017, and we expect to have enrolled all 110 participants by December 2017. Results are expected in June 2018.

Conclusions: If ivermectin treatment in addition to AEDs is able to lead to seizure freedom or significantly reduces seizure frequency in OAE patients, this will have major consequences for epilepsy treatment in onchocerciasis-endemic regions. Ivermectin is donated for free and in non Loa-Loa-endemic regions has negligible side effects. Reducing the burden of epilepsy will have a major impact on quality of life and socioeconomic status of families with affected members in Africa.

Trial registration: ClinicalTrials.gov NCT03052998; https://ichgcp.net/clinical-trials-registry/NCT03052998 (Archived by WebCite at http://www.webcitation.org/6roFVQSG0).

Keywords: Democratic Republic of the Congo; epilepsy; ivermectin; nodding syndrome; onchocerciasis; randomized clinical trial.

Conflict of interest statement

Conflicts of Interest: None declared.

©Robert Colebunders, Michel Mandro, Deby Mukendi, Housseini Dolo, Patrick Suykerbuyk, Marieke Van Oijen. Originally published in JMIR Research Protocols (http://www.researchprotocols.org), 30.08.2017.

References

    1. Pion SDS, Boussinesq M. Significant association between epilepsy and presence of onchocercal nodules: case-control study in Cameroon. Am J Trop Med Hyg. 2012 Mar;86(3):557. doi: 10.4269/ajtmh.2012.11-0603a.
    1. Pion SDS, Kaiser C, Boutros-Toni F, Cournil A, Taylor MM, Meredith SEO, Stufe A, Bertocchi I, Kipp W, Preux P, Boussinesq M. Epilepsy in onchocerciasis endemic areas: systematic review and meta-analysis of population-based surveys. PLoS Negl Trop Dis. 2009 Jun 16;3(6):e461. doi: 10.1371/journal.pntd.0000461.
    1. Boussinesq M, Pion SDS, Demanga N, Kamgno J. Relationship between onchocerciasis and epilepsy: a matched case-control study in the Mbam Valley, Republic of Cameroon. Trans R Soc Trop Med Hyg. 2002;96(5):537–541.
    1. Tumwine JK, Vandemaele K, Chungong S, Richer M, Anker M, Ayana Y, Opoka ML, Klaucke DN, Quarello A, Spencer PS. Clinical and epidemiologic characteristics of nodding syndrome in Mundri County, southern Sudan. Afr Health Sci. 2012 Sep;12(3):242–248.
    1. Dowell S, Sejvar J, Riek L, Vandemaele K, Lamunu M, Kuesel A. Nodding syndrome. Emerg Infect Dis. 2013;19(9):1374–1384.
    1. Sejvar J, Kakooza A, Foltz J, Makumbi I, Atai-Omoruto A, Malimbo M. Clinical, neurological, and electrophysiological features of nodding syndrome in Kitgum, Uganda: an observational case series. Lancet Neurol. 2013;12(2):166–174.
    1. Musisi S, Akena D, Nakimuli-Mpungu E, Abbo C, Okello J. Neuropsychiatric perspectives on nodding syndrome in northern Uganda: a case series study and a review of the literature. Afr Health Sci. 2013;13(2):205–218.
    1. Idro R, Opoka R, Aanyu H, Kakooza-Mwesige A, Piloya-Were T, Namusoke H. Nodding syndrome in Ugandan children—clinical features, brain imaging and complications: a case series. BMJ Open. 2013;3(5)
    1. Wamala J, Malimbo M, Tepage F, Lukwago L, Okot C, Cannon R. Nodding syndrome may be only the ears of the hippo. PLoS Negl Trop Dis. 2015;9(8):e0003880.
    1. Colebunders R, Hendy A, van Oijen M. Nodding syndrome in onchocerciasis endemic areas. Trends Parasitol. 2016;32(8):581–583.
    1. González P, González FA, Ueno K. Ivermectin in human medicine: an overview of the current status of its clinical applications. Curr Pharm Biotechnol. 2012 May;13(6):1103–1109.
    1. Colebunders R, Post R, O'Neill S, Haesaert G, Opar B, Lakwo T. Nodding syndrome since 2012: recent progress, challenges and recommendations for future research. Trop Med Int Health. 2015;20(2):194–200.
    1. Colebunders R, Mandro M, Mokili J, Mucinya G, Mambandu G, Pfarr K. Risk factors for epilepsy in Bas-Uele Province, Democratic Republic of the Congo: a case-control study. Int J Infect Dis. 2016;49:1–8.
    1. Dozie I, Onwuliri C, Nwoke B, Chukwuocha U, Chikwendu C, Okoro I. Onchocerciasis and epilepsy in parts of the Imo river basin, Nigeria: a preliminary report. Public Health. 2006;120(5):448–450.
    1. Winkler AS, Friedrich K, Velicheti S, Dharsee J, König R, Nassri A, Meindl M, Kidunda A, Müller TH, Jilek-Aall L, Matuja W, Gotwald T, Schmutzhard E. MRI findings in people with epilepsy and nodding syndrome in an area endemic for onchocerciasis: an observational study. Afr Health Sci. 2013 Jun;13(2):529–540. doi: 10.4314/ahs.v13i2.51.
    1. Casis SG. [El sindrome epileptico y sus reaciones con onchocercosis] Boletin de Salubridad e Higiene. 1938;1:11–31.
    1. Mazotti L. [Presencia de microfilarias de onchocerca volvulus en el liquido cephaloraquideo de enfermos tratados con hetrazan] Revista del Instituto de Salubridad y Efermedades Tropicales. 1959;19:1–5.
    1. Duke BO, Vincelette J, Moore PJ. Microfilariae in the cerebrospinal fluid, and neurological complications, during treatment of onchocerciasis with diethylcarbamazine. Tropenmed Parasitol. 1976 Jun;27(2):123–132.
    1. Taylor HR, Greene BM. Ocular changes with oral and transepidermal diethylcarbamazine therapy of onchocerciasis. Br J Ophthalmol. 1981 Jul;65(7):494–502.
    1. Idro R, Opar B, Wamala J, Abbo C, Onzivua S, Mwaka DA, Kakooza-Mwesige A, Mbonye A, Aceng JR. Is nodding syndrome an Onchocerca volvulus-induced neuroinflammatory disorder? Uganda's story of research in understanding the disease. Int J Infect Dis. 2016 Apr;45:112–117. doi: 10.1016/j.ijid.2016.03.002.
    1. Edwards G. Ivermectin: does P-glycoprotein play a role in neurotoxicity? Filaria J. 2003 Oct 24;2 Suppl 1:S8. doi: 10.1186/1475-2883-2-S1-S8.
    1. Duke BO, Zea-Flores G, Castro J, Cupp EW, Munoz B. Comparison of the effects of a single dose and of four six-monthly doses of ivermectin on adult Onchocerca volvulus. Am J Trop Med Hyg. 1991 Jul;45(1):132–137.
    1. Basáñez M, Pion SDS, Boakes E, Filipe JAN, Churcher TS, Boussinesq M. Effect of single-dose ivermectin on onchocerca volvulus: a systematic review and meta-analysis. Lancet Infect Dis. 2008 May;8(5):310–322. doi: 10.1016/S1473-3099(08)70099-9.
    1. Kipp W, Burnham G, Kamugisha J. Improvement in seizures after ivermectin. Lancet. 1992 Sep 26;340(8822):789–790.
    1. Colebunders R, Tepage F, Kashama J, Levick B, Mandro M, Komba M, Tagoto A, Suykerbuyk P, Battina K, Laudisoit A. Onchocerciasis associated epilepsy in the Democratic Republic of the Congo. International Congress for Tropical Medicine and Malaria; 2016; Brisbane. 2016.
    1. Birbeck GL, Kalichi EMN. Epilepsy prevalence in rural Zambia: a door-to-door survey. Trop Med Int Health. 2004 Jan;9(1):92–95.
    1. Ngugi AK, Bottomley C, Kleinschmidt I, Wagner RG, Kakooza-Mwesige A, Ae-Ngibise K, Owusu-Agyei S, Masanja H, Kamuyu G, Odhiambo R, Chengo E, Sander JW, Newton CR, SEEDS group Prevalence of active convulsive epilepsy in sub-Saharan Africa and associated risk factors: cross-sectional and case-control studies. Lancet Neurol. 2013 Mar;12(3):253–263. doi: 10.1016/S1474-4422(13)70003-6.
    1. Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE, Engel J, Forsgren L, French JA, Glynn M, Hesdorffer DC, Lee BI, Mathern GW, Moshé SL, Perucca E, Scheffer IE, Tomson T, Watanabe M, Wiebe S. ILAE official report: a practical clinical definition of epilepsy. Epilepsia. 2014 Apr;55(4):475–482. doi: 10.1111/epi.12550. doi: 10.1111/epi.12550.
    1. World Health Organisation Epilepsy: a manuel for clinical officers in Africa. [2017-07-06]. .
    1. Hopkins A. From “control to elimination:” a strategic change to win the end game. Int Health. 2015;7(5):304–305.
    1. Duke BO, Zea-Flores G, Gannon RT. On the reproductive activity of the female onchocerca volvulus. Trop Med Parasitol. 1990 Dec;41(4):387–402.
    1. Duke BO, Zea-Flores G, Muñoz B. The embryogenesis of onchocerca volvulus over the first year after a single dose of ivermectin. Trop Med Parasitol. 1991 Sep;42(3):175–180.
    1. Gardon J, Boussinesq M, Kamgno J, Gardon-Wendel N, Demanga N, Duke BOL. Effects of standard and high doses of ivermectin on adult worms of onchocerca volvulus: a randomised controlled trial. Lancet. 2002 Jul 20;360(9328):203–210. doi: 10.1016/S0140-6736(02)09456-4.
    1. Kamgno J, Gardon J, Gardon-Wendel N, Demanga N, Duke BOL, Boussinesq M. Adverse systemic reactions to treatment of onchocerciasis with ivermectin at normal and high doses given annually or three-monthly. Trans R Soc Trop Med Hyg. 2004 Aug;98(8):496–504. doi: 10.1016/j.trstmh.2003.10.018.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner